Better Health for All

Famicord AG's core business, stem cell banking and therapies, is entirely devoted to health improvement, providing stem cells for the treatment of over 7,000 patients and releasing over 7,550 therapies by May 2025 for conditions like inherited blood disorders, cancers, brain injuries, and neurodevelopmental disorders.

The company has no reported revenue from products with negative health outcomes. However, the company's services are expensive, with Famicord acknowledging "High prices in some markets" and actively working to lower them. Access for vulnerable populations is limited, with only a "Targeted Storage" program mentioned without details on its reach or impact. Risk transparency is poor, as company brochures tout benefits but downplay the low likelihood of use, and there is no comprehensive public data on risks and benefits. The company received a 3 million Euro grant for ALS treatment development, but this represents a small portion of its overall operations, and no overall R&D budget share is provided. While Famicord states a commitment to educating families, specific programs or their impact are not detailed. The company conducts clinical trials and mentions ethical considerations like informed consent and ethical committee approvals, but lacks specific data on diversity, inclusion, or full results transparency.

Fair Money & Economic Opportunity

Famicord AG operates in the healthcare sector, specializing in the collection, processing, and storage of umbilical cord blood stem cells.

The company does not offer lending, deposit, or other consumer financial services. Therefore, all KPIs related to financial products, services, and their impact on economic opportunity are not applicable to its core business model. While Famicord uses a subscription-based pricing model for its stem cell storage services and operates public cord blood banking programs, these activities do not fall under the scope of financial services as defined by the rubric.

Fair Pay & Worker Respect

The provided article, 'Summary of VITA 34 AG Code of Conduct', pertains to VITA 34 AG.

There is no information within the article that explicitly links this code of conduct or any of its contents to Famicord AG, the company being assessed. Therefore, no evidence is available to score any of the KPIs for Famicord AG.

Fair Trade & Ethical Sourcing

The provided article, VITA 34 AG's Code of Conduct, outlines general commitments to legal compliance, ethical conduct, and human rights, including reporting channels for suspected violations.

However, it does not contain any quantitative data or specific metrics related to fair trade certifications, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend. Therefore, no KPIs can be scored based on the evidence.

Honest & Fair Business

Famicord AG has a comprehensive, Group-wide whistleblower policy, operational since January 1, 2024, which is compliant with the EU Whistleblower Directive 2019/1937/EU.

It includes internal reporting offices, with separate ones for subsidiaries with at least 50 employees where legally required. The policy offers secure, confidential, and mostly anonymous reporting via a digital system operated by an independent third-party provider, email, post, or directly to a compliance officer, ensuring protection against retaliation. Receipt of reports is confirmed within 7 days, and feedback on planned measures is provided within three months. The company also introduced an Anti-Corruption Code in the whole Group in fiscal year 2024, in force as of November 18, 2024. This code specifies basic rules of conduct to prevent corrupt behaviors, promotes ethical attitudes, and mandates periodic training for all employees. It prohibits all forms of corruption, including influence peddling, and requires due diligence for business partners. However, the median time to close customer or stakeholder ethics complaints is up to 3 months and 7 days (approximately 100 days), which is slower than desired.

Kind to Animals

Famicord AG specializes in the collection, processing, and storage of human umbilical cord blood stem cells.

The company's core business model does not involve products requiring cruelty-free certification, animal testing, animal-derived ingredients, animal agriculture operations, or activities that directly impact wildlife habitats. Therefore, all KPIs related to animal welfare, testing, sourcing, and conservation are not applicable to Famicord AG's operations, and no relevant evidence was found in the provided articles.

No War, No Weapons

No evidence was found in the provided articles regarding Famicord AG's involvement in arms manufacturing, military contracts, conflict facilitation, or any related activities.

The articles focus exclusively on the company's core business of cord blood stem cell banking and medical treatment programs, with explicit statements that no data relevant to 'No War, No Weapons' metrics is present.

Planet-Friendly Business

In 2023, Famicord AG sourced 41.77% of its operational energy consumption from renewables.

Water consumption for Vita 34 AG and PBKM was 1,529.45 m³ against a sales revenue of EUR 77.1 million, resulting in approximately 19.84 m³ per EUR 1 million revenue. Capital expenditure aligned with the EU Sustainable Taxonomy was 12.3% in 2023. The company reported zero major environmental compliance violations in 2023, with one compliance investigation at a Group company related to physician qualifications.

Respect for Cultures & Communities

The provided Code of Conduct for FamiCord Group outlines general ethical principles and compliance procedures.

However, it explicitly states that it does not contain specific data or metrics relevant to the 'Respect for Cultures & Communities' value or its associated KPIs. No quantitative data, regulatory actions, certifications, or comparisons to industry benchmarks are present in the text regarding these specific areas.

Safe & Smart Tech

The company states it is compliant with GDPR, BDSGneu, and other relevant laws.

It uses SSL technology with 256-bit or 128-bit v3 encryption. Users are granted rights to access, correct, delete, and restrict data processing, and withdraw consent. The company also states that data collected is limited to what is necessary for the purpose and is deleted when no longer needed.